Nektar Therapeutics
NKTR
241 hedge funds and large institutions have $951M invested in Nektar Therapeutics in 2022 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 88 increasing their positions, 66 reducing their positions, and 40 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 66
8% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 40
0.12% more ownership
Funds ownership: 94.34% → 94.46% (+0.12%)
0% more funds holding
Funds holding: 241 → 241 (0)
17% less call options, than puts
Call options by funds: $31.5M | Put options by funds: $38M
60% less capital invested
Capital invested by funds: $2.35B → $951M (-$1.4B)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$9.58M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.06M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$8.56M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$8.17M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$64.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$13.3M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
-$10.2M |
| 4 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
-$7.57M |
| 5 |
BlackRock
New York
|
-$5.5M |
NKTR Hedge Fund Activity: Q1 2022 in Review
241 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2022, worth a combined $951M — down 60% from $2.35B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new NKTR positions and 40 closed out — a net gain of 3 holders — while 88 added to existing stakes and 66 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $9.58M. The largest seller was Fidelity Investments, cutting an estimated $64.2M.
- 241 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $951M of Nektar Therapeutics stock for Q1 2022, down 60% quarter-over-quarter.
- 43 funds opened new Nektar Therapeutics positions in Q1 2022 and 40 closed out, a net change of +3 holders.
- The largest Nektar Therapeutics buyer in Q1 2022 was First Trust Advisors, an estimated $9.58M added.
- The largest Nektar Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $64.2M sold.
Based on aggregated 13F filings for Q1 2022.